{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:46:39Z","timestamp":1789983999084,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL124074"],"award-info":[{"award-number":["HL124074"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["142579"],"award-info":[{"award-number":["142579"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL116273"],"award-info":[{"award-number":["T32 HL116273"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007557","name":"California Institute of Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-13009"],"award-info":[{"award-number":["DISC2-13009"]}],"id":[{"id":"10.13039\/100007557","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>TY1, a synthetic non-coding RNA (ncRNA) bioinspired by small Y RNAs abundant in extracellular vesicles (EVs), decreases cGAS\/STING activation in myocardial infarction and thereby attenuates inflammation. Motivated by the concept that heart failure with preserved ejection fraction (HFpEF) is a systemic inflammatory disease, we tested TY1 in a murine model of HFpEF. Intravenous TY1, packaged in a transfection reagent, reversed the cardiac and systemic manifestations of HFpEF in two-hit obese-hypertensive mice, without inducing weight loss. The effects of TY1 were specific, insofar as they were not reproduced by a control RNA of the same nucleotide content but in scrambled order. TY1 consistently suppressed myocardial stress-induced MAP kinase signaling, as well as downstream inflammatory, fibrotic, and hypertrophic gene pathways in heart tissue. TY1 not only prevented but actually reversed key pathological processes underlying HFpEF, with no evidence of toxicity. Most noteworthy from a practical perspective, the effects of intravenous TY1 were reproduced by feeding HFpEF mice an oral micellar formulation of TY1. As the prototype for a novel class of ncRNA drugs which target cell stress, TY1 exhibits exceptional disease-modifying bioactivity in HFpEF.<\/jats:p>","DOI":"10.1007\/s00395-024-01095-5","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T10:59:24Z","timestamp":1735642764000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intravenous and oral administration of the synthetic RNA drug, TY1, reverses heart failure with preserved ejection fraction in mice"],"prefix":"10.1007","volume":"120","author":[{"given":"Kazutaka","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xaviar M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukuro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ciullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Godoy","family":"Coto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Tsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Marb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-7432","authenticated-orcid":false,"given":"Ahmed Gamal-Eldin","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, Investigators EM-PT (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00395-019-0722-5","volume":"114","author":"L Bacmeister","year":"2019","unstructured":"Bacmeister L, Schwarzl M, Warnke S, Stoffers B, Blankenberg S, Westermann D, Lindner D (2019) Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol 114:19. https:\/\/doi.org\/10.1007\/s00395-019-0722-5","journal-title":"Basic Res Cardiol"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","volume":"118","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ (2023) Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 118:3434\u20133450. https:\/\/doi.org\/10.1093\/cvr\/cvac120","journal-title":"Cardiovasc Res"},{"key":"1095_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMe2033176","volume":"384","author":"FC Brosius","year":"2021","unstructured":"Brosius FC, Vandvik PO (2021) Cardioprotection with yet another SGLT2 inhibitor - an embarrassment of riches. N Engl J Med 384:179\u2013181. https:\/\/doi.org\/10.1056\/NEJMe2033176","journal-title":"N Engl J Med"},{"key":"1095_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN, Committees ST-HT, Investigators (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 403:1635\u20131648. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0","journal-title":"Lancet"},{"key":"1095_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14560","author":"G Cimino","year":"2023","unstructured":"Cimino G, Vaduganathan M, Lombardi CM, Pagnesi M, Vizzardi E, Tomasoni D, Adamo M, Metra M, Inciardi RM (2023) Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.14560","journal-title":"ESC Heart Fail"},{"key":"1095_CR7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1161\/CIRCULATIONAHA.107.762229","volume":"118","author":"BR Davis","year":"2008","unstructured":"Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S, Group ACR (2008) Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 118:2259\u20132267. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.762229","journal-title":"Circulation"},{"key":"1095_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/CIRCULATIONAHA.120.050498","volume":"143","author":"VS Hahn","year":"2021","unstructured":"Hahn VS, Knutsdottir H, Luo X, Bedi K, Margulies KB, Haldar SM, Stolina M, Yin J, Khakoo AY, Vaishnav J, Bader JS, Kass DA, Sharma K (2021) Myocardial gene expression signatures in human heart failure with preserved ejection fraction. Circulation 143:120\u2013134. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050498","journal-title":"Circulation"},{"key":"1095_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-022-00909-8","volume":"117","author":"G Heusch","year":"2022","unstructured":"Heusch G (2022) Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol 117:1. https:\/\/doi.org\/10.1007\/s00395-022-00909-8","journal-title":"Basic Res Cardiol"},{"key":"1095_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.20.581294","author":"AG-E Ibrahim","year":"2024","unstructured":"Ibrahim AG-E, Ciullo A, Miyamoto K, Liao K, Jones XM, Yamaguchi S, Li C, Rannou A, Nawaz A, Morris A, Tsi K, Marb\u00e1n CH, Lee J, Manriquez N, Hong Y, Kumar AN, Dawkins JF, Rogers RG, Marb\u00e1n E (2024) Augmentation of DNA exonuclease TREX1 in macrophages as a therapy for cardiac ischemic injury. Biorxiv. https:\/\/doi.org\/10.1101\/2024.02.20.581294","journal-title":"Biorxiv"},{"key":"1095_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41551-019-0448-6","volume":"3","author":"AGE Ibrahim","year":"2019","unstructured":"Ibrahim AGE, Li C, Rogers R, Fournier M, Li L, Vaturi SD, Antes T, Sanchez L, Akhmerov A, Moseley JJ, Tobin B, Rodriguez-Borlado L, Smith RR, Marban L, Marban E (2019) Augmenting canonical Wnt signalling in therapeutically inert cells converts them into therapeutically potent exosome factories. Nat Biomed Eng 3:695\u2013705. https:\/\/doi.org\/10.1038\/s41551-019-0448-6","journal-title":"Nat Biomed Eng"},{"key":"1095_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC, CommitteesInvestigators ST-HT (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"1095_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01074-w","author":"JD Lanzer","year":"2024","unstructured":"Lanzer JD, Wienecke LM, Ramirez Flores RO, Zylla MM, Kley C, Hartmann N, Sicklinger F, Schultz JH, Frey N, Saez-Rodriguez J, Leuschner F (2024) Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fraction. Basic Res Cardiol. https:\/\/doi.org\/10.1007\/s00395-024-01074-w","journal-title":"Basic Res Cardiol"},{"key":"1095_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/CIRCRESAHA.124.323058","volume":"135","author":"E Marban","year":"2024","unstructured":"Marban E (2024) Deconstructing regenerative medicine: from mechanistic studies of cell therapy to novel bioinspired RNA drugs. Circ Res 135:877\u2013885. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.323058","journal-title":"Circ Res"},{"key":"1095_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s002100000363","volume":"363","author":"MC Michel","year":"2001","unstructured":"Michel MC, Li Y, Heusch G (2001) Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol 363:245\u2013266. https:\/\/doi.org\/10.1007\/s002100000363","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1095_CR16","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","volume":"130","author":"J Roh","year":"2022","unstructured":"Roh J, Hill JA, Singh A, Valero-Munoz M, Sam F (2022) Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models. Circ Res 130:1906\u20131925. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.320257","journal-title":"Circ Res"},{"key":"1095_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, Luo X, Jiang N, May HI, Wang ZV, Hill TM, Mammen PPA, Huang J, Lee DI, Hahn VS, Sharma K, Kass DA, Lavandero S, Gillette TG, Hill JA (2019) Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568:351\u2013356. https:\/\/doi.org\/10.1038\/s41586-019-1100-z","journal-title":"Nature"},{"key":"1095_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac463","author":"AM Shah","year":"2022","unstructured":"Shah AM, Giacca M (2022) Small non-coding RNA therapeutics for cardiovascular disease. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac463","journal-title":"Eur Heart J"},{"key":"1095_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, CommitteesInvestigators DT (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA (2021) Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov 20:629\u2013651. https:\/\/doi.org\/10.1038\/s41573-021-00219-z","journal-title":"Nat Rev Drug Discov"},{"key":"1095_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00392-020-01633-w","volume":"109","author":"J Wintrich","year":"2020","unstructured":"Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, Laufs U, Tschope C, Anker SD, Lam CSP, Voors AA, Bohm M (2020) Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol 109:1079\u20131098. https:\/\/doi.org\/10.1007\/s00392-020-01633-w","journal-title":"Clin Res Cardiol"},{"key":"1095_CR22","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1093\/eurheartj\/ehab389","volume":"42","author":"C Withaar","year":"2021","unstructured":"Withaar C, Lam CSP, Schiattarella GG, de Boer RA, Meems LMG (2021) Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. Eur Heart J 42:4420\u20134430. https:\/\/doi.org\/10.1093\/eurheartj\/ehab389","journal-title":"Eur Heart J"},{"key":"1095_CR23","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.27.591474","author":"S Yamaguchi","year":"2024","unstructured":"Yamaguchi S, Miyamoto K, Jones XM, Ciullo A, Morris A, Tsi K, Marban E, Ibrahim AGE (2024) Oral bioavailability of a noncoding RNA drug, TY1, that acts on macrophages. Biorxiv. https:\/\/doi.org\/10.1101\/2024.04.27.591474","journal-title":"Biorxiv"}],"container-title":["Basic Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-024-01095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00395-024-01095-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-024-01095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T11:01:51Z","timestamp":1744023711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00395-024-01095-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s00395-024-01095-5","relation":{},"ISSN":["1435-1803"],"issn-type":[{"value":"1435-1803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.M. owns founder\u2019s equity, and AGI owns stock, in Capricor Therapeutics, a company with no licensing rights to TY1 or related discoveries. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}